Daily Judi: Thursday, September 29, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Fierce Biotech looks at CytoDyn, and the company’s pivot away from COVID-19 therapeutics to focus on oncology.
Nature profiles University of Wisconsin–Madison scientist Dave O’Connor and his teams’ efforts to pinpoint a unique mutation of SARS-CoV-2 through the Wisconsin waste water of over 100,000 people.
Danish pharmaceutical company, Novo Nordisk, agreed to purchase a lead experimental anti-inflammatory drug, VENT-01, made by Ventus Therapeutics, for $70 million. (BioPharma Dive)
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
“We are small enough that we are nimble, so we can prioritize quickly, yet also of significant size that we allocate resources where needed. We truly do a lot. This is my dream job. Judi allows me to have a bigger impact. And we do great work.”
–Jess, Program Manager
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.